var data={"title":"Bosentan: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Bosentan: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5755?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=bosentan-drug-information\" class=\"drug drug_general\">see &quot;Bosentan: Drug information&quot;</a> and <a href=\"topic.htm?path=bosentan-patient-drug-information\" class=\"drug drug_patient\">see &quot;Bosentan: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708663\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Distribution program:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Because of the risks of hepatotoxicity and birth defects, bosentan is available only through a restricted program called the Tracleer REMs Program. The Tracleer REMs Program is a component of the bosentan Risk Evaluation and Mitigation Strategy (REMS). Under the bosentan REMS, prescribers, patients, and pharmacies must enroll in the program.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hepatotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">In clinical studies, bosentan caused at least a 3-fold upper limit of normal (ULN) elevation of liver aminotransferases (ALT and AST) in about 11% of patients, accompanied by elevated bilirubin in a small number of cases. Because these changes are a marker for potential serious hepatotoxicity, serum aminotransferase levels must be measured prior to initiation of treatment and then monthly. In the postmarketing period, in the setting of close monitoring, rare cases of unexplained hepatic cirrhosis were reported after prolonged (more than 12 months) therapy with bosentan in patients with multiple comorbidities and drug therapies. There have also been reports of liver failure. The contribution of bosentan in these cases could not be excluded.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">In at least 1 case, the initial presentation of hepatotoxicity (after more than 20 months of treatment) included pronounced elevations in aminotransferases and bilirubin levels accompanied by nonspecific symptoms, all of which resolved slowly over time after discontinuation of bosentan. This case reinforces the importance of strict adherence to the monthly monitoring schedule for the duration of treatment and the treatment algorithm, which includes stopping bosentan if a rise of aminotransferase accompanied by signs or symptoms of liver dysfunction occurs.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Elevations in aminotransferases require close attention. Generally, avoid using bosentan in patients with elevated aminotransferases (greater than 3 times the ULN) at baseline because monitoring for hepatotoxicity may be more difficult. Stop treatment with bosentan if liver aminotransferase elevations are accompanied by clinical symptoms of hepatotoxicity (eg, abdominal pain, fever, jaundice, nausea, unusual lethargy or fatigue, vomiting) or increases in bilirubin 2 times the ULN or greater. There is no experience with the reintroduction of bosentan in these circumstances.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Embryo-fetal toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan is likely to cause major birth defects if used by pregnant women based on animal data. Therefore, pregnancy must be excluded before the start of treatment with bosentan. Throughout treatment and for 1 month after stopping bosentan, women of childbearing potential must use 2 reliable methods of contraception unless the patient has an intrauterine device (IUD) or tubal sterilization in which case no other contraception is needed. Hormonal contraceptives, including oral, injectable, transdermal, and implantable contraceptives, should not be used as the sole means of contraception because these may not be effective in patients receiving bosentan. Obtain monthly pregnancy tests.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142201\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Tracleer</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142202\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Tracleer</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2851892\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Endothelin Receptor Antagonist</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442087\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Persistant pulmonary hypertension (PPHN):</b> Very limited data available: Full-term neonate: Oral: 1 mg/kg/dose twice daily short-term use (2 to 16 days) in three full-term neonates has been reported. In the initial report, two full-term neonates (8 days and 14 days old) with persistent pulmonary hypertension of the newborn (PPHN) and transposition of the great arteries received bosentan prior to cardiac surgery; patients also received other therapies (Goissen 2008). A case report describes the use of bosentan monotherapy for PPHN in a full-term neonate as primary course of treatment initiated at 29 hours of life; therapy was weaned after 72 hours through the following dose reductions: 0.5 mg/kg/dose twice daily followed by 0.5 mg/kg once daily and subsequent discontinuation at 96 hours of treatment (Nakwan 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2851924\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=bosentan-drug-information\" class=\"drug drug_general\">see &quot;Bosentan: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pulmonary arterial hypertension: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;7 months and Children: Limited data available (Barst 2003; Ivy 2004; Maiya 2006; Rosenzweig 2005):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Fixed dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">5 to &lt;10 kg: Initial: 15.6 mg daily for 4 weeks; increase to maintenance dose of 15.6 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">10 to 20 kg: Initial: 31.25 mg daily for 4 weeks; increase to maintenance dose of 31.25 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;20 to 40 kg: Initial: 31.25 mg twice daily for 4 weeks; increase to maintenance dose of 62.5 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;40 kg: Initial: 62.5 mg twice daily for 4 weeks; increase to maintenance dose of 125 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weight-based dosing: Children &ge;2 years: Initial: 0.75 to 1 mg/kg/dose twice daily for 4 weeks (maximum dose: 62.5 mg); then increase to maintenance dose of 2 mg/kg/dose twice daily (maximum dose: &le;40 kg: 62.5 mg; maximum dose: &gt;40 kg: 125 mg); a higher daily dose of 4 mg/kg/dose twice daily has been studied but has not been shown to produce higher serum concentrations than 2 mg/kg/dose and is not recommended by authors of the trial (Beghetti 2009; Beghetti 2009a, Villanueva 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &lt;40 kg: Initial and maintenance: 62.5 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;40 kg: Initial: 62.5 mg twice daily for 4 weeks; increase to maintenance dose of 125 mg twice daily; <b>Note:</b> Doses &gt;125 mg twice daily do not provide additional benefit sufficient to offset the increased risk of hepatic injury. When discontinuing treatment, consider a reduction in dosage to 62.5 mg twice daily for 3 to 7 days to avoid clinical deterioration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment with concomitant protease inhibitor therapy:</b> There are no pediatric-specific recommendations; based on experience in adult patients, dosage adjustment suggested for concurrent use with atazanavir/ritonavir, darunavir/ritonavir, fosamprenavir, indinavir, lopinavir/ritonavir, nelfinavir, ritonavir, saquinavir/ritonavir, or tipranavir/ritonavir.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pulmonary arterial hypertension:</b> Initial: 62.5 mg twice daily for 4 weeks; increase to maintenance dose of 125 mg twice daily; adults &lt;40 kg should be maintained at 62.5 mg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Doses &gt;125 mg twice daily do not provide additional benefit sufficient to offset the increased risk of hepatic injury. When discontinuing treatment, consider a reduction in dosage to 62.5 mg twice daily for 3 to 7 days (to avoid clinical deterioration).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Coadministration with protease inhibitor regimen:</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dosage adjustment for concurrent use with atazanavir/ritonavir, darunavir/ritonavir, fosamprenavir, lopinavir/ritonavir, ritonavir, saquinavir/ritonavir, tipranavir/ritonavir:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Coadministration of bosentan in patients currently receiving one of these protease inhibitor regimens for at least 10 days: Begin with bosentan 62.5 mg once daily or every other day based on tolerability</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Coadministration of one of these protease inhibitor regimens in patients currently receiving bosentan: Discontinue bosentan at least 36 hours prior to the initiation of an above protease inhibitor regimen. After at least 10 days of the protease inhibitor regimen, resume bosentan 62.5 mg once daily or every other day based on tolerability</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dosage adjustment for concurrent use with indinavir or nelfinavir:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Coadministration of bosentan in patients currently receiving indinavir or nelfinavir: Begin with bosentan 62.5 mg once daily or every other day based on tolerability</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Coadministration of indinavir or nelfinavir in patients currently receiving bosentan: Adjust bosentan to 62.5 mg once daily or every other day based on tolerability</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> No dosage adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Adolescents and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild impairment (Child-Pugh class A): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate to severe impairment (Child-Pugh class B and C) and/or baseline transaminase &gt;3 times ULN: Use not recommended; systemic exposure significantly increased in patients with moderate impairment (not studied in patients with severe impairment).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for toxicity: </b>The presented dosing adjustments are based on experience in adult patients; specific recommendations for pediatric patients are limited. Refer to specific protocol for management in pediatric patients if available.<b></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatotoxicity: If any elevation, regardless of degree, is accompanied by clinical symptoms of hepatic injury (unusual fatigue, nausea, vomiting, abdominal pain, fever, or jaundice) or a serum bilirubin &ge;2 times ULN, treatment should be stopped.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">AST/ALT &gt;3 times but &le;5 times ULN: Confirm elevation with additional test; if confirmed, reduce dose to 62.5 mg or interrupt treatment. Monitor transaminase levels at least every 2 weeks. May continue or reintroduce treatment, as appropriate, following return to pretreatment aminotransferase values. When reintroducing treatment, begin with starting dose and recheck transaminases within 3 days and at least every 2 weeks thereafter.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">AST/ALT &gt;5 times but &le;8 times upper limit of normal: Confirm elevation with additional test; if confirmed, stop treatment. Monitor transaminase levels at least every 2 weeks. May reintroduce treatment, as appropriate, following return to pretreatment aminotransferase values. When reintroducing treatment, begin with starting dose and recheck transaminases within 3 days and at least every 2 weeks thereafter.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">AST/ALT &gt;8 times upper limit of normal: Stop treatment and do not reintroduce.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142181\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tracleer: 62.5 mg, 125 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Soluble, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tracleer: 32 mg [scored; contains aspartame]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142166\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874386\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209279s000lbl.pdf#page=30&amp;token=YULROONLs2h34rivBrrVzsW99NvhvrIiFJH4l93pkiqfrfRHJopEy4kmeIm1ReGCd/x9Fui0LynjUYum69cliZ9VpXrR7DZb0QUJ9nwcGqK5Ns61lP0zyUBJj7coyerV&amp;TOPIC_ID=13087\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209279s000lbl.pdf#page=30</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2851925\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: May be administered without regard to meals. Avoid grapefruit and grapefruit juice. Women of childbearing potential should avoid splitting, crushing, or handling broken tablets and exposure to the generated dust (tablets should be dissolved in water if necessary).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130909\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142196\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store film-coated and dispersible tablets at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Store divided dispersible tablet pieces in the opened blister for up to 7 days.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2851893\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of pulmonary arterial hypertension (PAH) [WHO Group I] in patients with NYHA Class II, III, or IV symptoms to improve exercise capacity and decrease the rate of clinical deterioration (FDA approved in ages &gt;12 years and adults); <b>Note:</b> Clinical trials establishing effectiveness included primarily patients with NYHA Functional Class II-IV symptoms.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6053349\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Tracleer may be confused with TriCor</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142229\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Chest pain, edema, flushing, hypotension, palpitations, syncope</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Fluid retention</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum ALT (dose-related), increased serum AST (dose-related)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Respiratory tract infection, sinusitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylaxis, DRESS syndrome, fluid retention, hepatic cirrhosis (prolonged therapy), hepatic failure (rare), hypersensitivity reaction, leukopenia, neutropenia, severe anemia, skin rash, thrombocytopenia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142186\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to bosentan or any component of the formulation; concurrent use of cyclosporine or glyburide; use in women who are or may become pregnant.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling): Moderate to severe hepatic impairment (eg, ALT or AST &gt;3 times ULN, particularly when total bilirubin &gt;2 times ULN).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142170\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid retention/peripheral edema: Development of peripheral edema due to treatment and/or disease state (pulmonary arterial hypertension) may occur. There have also been postmarketing reports of fluid retention requiring treatment (eg, diuretics, fluid management, hospitalization) for heart failure. If clinically significant fluid retention develops (with or without weight gain), further evaluation is necessary to determine cause and appropriate treatment or discontinuation of therapy. Use with caution in patients with underlying heart failure due to potential complications from fluid retention. In a scientific statement from the American Heart Association, bosentan has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: Dose-related decreases in hematocrit/hemoglobin may be observed, usually within the first few weeks of therapy with subsequent stabilization of levels by 4 to 12 weeks of treatment. Monitor hemoglobin prior to treatment initiation, after 1 and 3 months, and every 3 months thereafter. Significant decreases in hemoglobin require further evaluation to determine the cause and specific management.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity:<b> [US Boxed Warning]: Bosentan is associated with transaminase elevations (ALT or AST &ge;3 times ULN), and in a small number of cases may occur with elevations in bilirubin. Monitor transaminases at baseline then monthly thereafter. Adjust dosage if elevations in liver enzymes occur without symptoms of hepatic injury or elevated bilirubin. In the postmarketing surveillance (with close monitoring), there have been rare cases of unexplained hepatic cirrhosis after prolonged therapy (&gt;12 months) in patients with multiple comorbidities and drug therapies. There have also been cases of hepatic failure. Treatment should be stopped in patients who develop elevated transaminases either in combination with symptoms of hepatic injury (unusual fatigue, jaundice, nausea, vomiting, abdominal pain, and/or fever) or elevated bilirubin (&ge;2 times ULN); safety of reintroduction is unknown. Avoid use in patients with baseline serum transaminases &gt;3 times ULN at baseline (monitoring for hepatotoxicity may be more difficult) or moderate to severe hepatic impairment.</b> The combination of hepatocellular injury (transaminase elevations &gt;3 times ULN) and bilirubin increased &ge;2 times ULN are a marker for potential serious hepatotoxicity. Transaminase elevations are dose dependent, generally asymptomatic, occur both early and late in therapy, progress slowly, and are usually reversible after treatment interruption or discontinuation. Transaminase elevations may also spontaneously reverse while continuing bosentan treatment. Consider the benefits of treatment versus the risk of hepatotoxicity when initiating therapy in patients with WHO Class II symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions, including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), anaphylaxis, rash and angioedema have been observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Spermatogenesis: Decreased sperm counts have been observed in men during treatment; bosentan may have an adverse effect on spermatogenesis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary veno-occlusive disease: If signs of pulmonary edema occur, consider possibility of pulmonary veno-occlusive disease; may require discontinuation of bosentan.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: <b>[US Boxed Warning]: Bosentan is likely to cause major birth defects if used by pregnant women based on animal data. Therefore, pregnancy must be excluded before the start of treatment with bosentan. Throughout treatment and for 1 month after stopping bosentan, women of childbearing potential must use 2 reliable methods of contraception unless the patient has an intrauterine device (IUD) or tubal sterilization in which case no other contraception is needed. Hormonal contraceptives, including oral, injectable, transdermal, and implantable contraceptives, should not be used as the sole means of contraception because these may not be effective in patients receiving bosentan. Obtain monthly pregnancy tests.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; REMS program:[US Boxed Warning]: Because of the risks of hepatotoxicity and birth defects, bosentan is only available through the Tracleer REMS Program. The Tracleer REMS Program is a component of the bosentan Risk Evaluation and Mitigation Strategy (REMS). Patients, prescribers, and pharmacies must enroll with the program. Call 1-866-228-3546 or visit http://www.tracleer.com/hcp/prescribing-tracleer.asp for more information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142217\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C9 (minor), CYP3A4 (minor), OATP1B1/SLCO1B1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Induces</b> CYP2C9 (weak), CYP3A4 (moderate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142174\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13087&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antihepaciviral Combination Products: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Antihepaciviral Combination Products. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: Bosentan may decrease the serum concentration of Atazanavir. Atazanavir may increase the serum concentration of Bosentan.  Management: Concurrent use of atazanavir (without ritonavir) and bosentan is not recommended.  Bosentan dose adjustments are required when used together with atazanavir/ritonavir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Axitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Axitinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bedaquiline: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Bedaquiline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzhydrocodone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Benzhydrocodone. Specifically, the serum concentrations of hydrocodone may be reduced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: Bosentan may decrease the serum concentration of Boceprevir. Boceprevir may increase the serum concentration of Bosentan. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Bosutinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clarithromycin: Bosentan may increase serum concentrations of the active metabolite(s) of Clarithromycin. Specifically, bosentan may increase concentrations of 14-hydroxyclarithromycin. Bosentan may decrease the serum concentration of Clarithromycin. Clarithromycin may increase the serum concentration of Bosentan.  Management: Consider alternative antimicrobial if possible. The clinical activity of clarithromycin may be altered, and increased bosentan toxicity may be expected.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of Bosentan. Management: See full drug interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobimetinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cobimetinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May increase the serum concentration of Bosentan. Bosentan may decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Moderate): May increase the serum concentration of Bosentan. Management: Concomitant use of both a CYP2C9 inhibitor and a CYP3A inhibitor or a single agent that inhibits both enzymes with bosentan is likely to cause a large increase in serum concentrations of bosentan and is not recommended.  See monograph for details.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Strong): May increase the serum concentration of Bosentan. Management: Concomitant use of both a CYP2C9 inhibitor and a CYP3A inhibitor or a single agent that inhibits both enzymes with bosentan is likely to cause a large increase in serum concentrations of bosentan and is not recommended. See monograph for details.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Bosentan. Management: Concomitant use of both a CYP2C9 inhibitor and a CYP3A inhibitor or a single agent that inhibits both enzymes with bosentan is likely to cause a large increase in serum concentrations of bosentan and is not recommended. See monograph for details.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Bosentan. Management: Concomitant use of both a CYP2C9 inhibitor and a CYP3A inhibitor or a single agent that inhibits both enzymes with bosentan is likely to cause a large increase in serum concentrations of bosentan and is not recommended. See monograph for details.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Substrates (High risk with Inducers): Bosentan may decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Daclatasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Daclatasvir.  Management: Increase the daclatasvir dose to 90 mg once daily if used with a moderate CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: Bosentan may decrease the serum concentration of Darunavir. Darunavir may increase the serum concentration of Bosentan.  Management: Use bosentan 62.5 mg/day or every other day in adults taking ritonavir- or cobicistat-boosted darunavir for at least 10 days. Stop bosentan for at least 36 hrs before starting boosted darunavir; wait at least 10 days before restarting bosentan.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasabuvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dasabuvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deflazacort: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Deflazacort. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Elbasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Elbasvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estriol (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Estriol (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estriol (Topical): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Estriol (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): Bosentan may decrease the serum concentration of Estrogen Derivatives (Contraceptive).  Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FentaNYL: CYP3A4 Inducers (Moderate) may decrease the serum concentration of FentaNYL. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Flibanserin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosamprenavir: Bosentan may decrease the serum concentration of Fosamprenavir. Fosamprenavir may increase the serum concentration of Bosentan.  Management: Use bosentan 62.5 mg/day or every other day in adult patients taking fosamprenavir for at least 10 days.  Temporarily stop bosentan (for at least 36 hrs) before starting fosamprenavir; wait at least 10 days before restarting bosentan.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gemfibrozil: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. See separate drug interaction monographs for agents listed as exceptions.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glecaprevir and Pibrentasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Glecaprevir and Pibrentasvir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GlyBURIDE: May enhance the hepatotoxic effect of Bosentan. GlyBURIDE may decrease the serum concentration of Bosentan. Bosentan may decrease the serum concentration of GlyBURIDE.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grazoprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Grazoprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GuanFACINE: CYP3A4 Inducers (Moderate) may decrease the serum concentration of GuanFACINE.  Management: Increase the guanfacine dose by up to double when initiating concomitant therapy with moderate CYP3A4 inducers. Increase guanfacine dose gradually over 1-2 weeks if moderate CYP3A4 inducer therapy is just beginning.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ibrutinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ifosfamide: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indinavir: May increase the serum concentration of Bosentan. Bosentan may decrease the serum concentration of Indinavir. Management: Initiate bosentan at, or adjust bosentan to, 62.5 mg once daily or every other day (based on tolerability) in indinavir-treated patients (see ritonavir for dosing if that agent is used). Additionally, monitor for possible reduced response to indinavir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lopinavir: May increase the serum concentration of Bosentan. Bosentan may decrease the serum concentration of Lopinavir. Management: Use bosentan 62.5 mg/day or every other day in adult patients taking lopinavir/ritonavir for at least 10 days.  Temporarily stop bosentan (for at least 36 hrs) before starting lopinavir/ritonavir; wait at least 10 days before restarting bosentan.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lurasidone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lurasidone.  Management: Monitor for decreased lurasidone effects if combined with moderate CYP3A4 inducers and consider increasing the lurasidone dose if coadministered with a moderate CYP3A4 inducer for 7 or more days.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: Bosentan may diminish the diagnostic effect of Macimorelin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirodenafil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mirodenafil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naldemedine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nelfinavir: May increase the serum concentration of Bosentan. Bosentan may decrease the serum concentration of Nelfinavir. Management: Initiate bosentan at, or adjust bosentan dose to, 62.5 mg once daily or every other day (based on tolerability) in patients who receive nelfinavir.  Additionally, monitor for possible reduced clinical response to nelfinavir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Neratinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nisoldipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nisoldipine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Olaparib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Olaparib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Palbociclib.  Management: The US label does not provide specific recommendations concerning use with moderate CYP3A4 inducers, but the Canadian label recommends avoiding use of moderate CYP3A4 inducers.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Perampanel.  Management: Increase the perampanel starting dose to 4 mg/day when perampanel is used concurrently with moderate and strong CYP3A4 inducers.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: Bosentan may decrease the serum concentration of Phosphodiesterase 5 Inhibitors. Phosphodiesterase 5 Inhibitors may increase the serum concentration of Bosentan. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): Bosentan may decrease the serum concentration of Progestins (Contraceptive).  Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ranolazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of Bosentan. Following the initial several weeks of concurrent rifampin, this effect is most likely. RifAMPin may increase the serum concentration of Bosentan. This effect is most likely to be observed within the initial few weeks of concurrent therapy (and may be greatest immediately following initiation of the combination). Management: Weekly monitoring of liver function tests during the first 4 weeks of concurrent therapy is recommended, with a return to normal recommended monitoring thereafter as appropriate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May increase the serum concentration of Bosentan. Management: Use bosentan 62.5 mg daily or every other day in adult patients who have been on ritonavir for at least 10 days.  Temporarily stop bosentan (for at least 36 hrs) before starting ritonavir; wait until at least 10 days on ritonavir before restarting.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rolapitant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Rolapitant. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saquinavir: Bosentan may decrease the serum concentration of Saquinavir. Saquinavir may increase the serum concentration of Bosentan.  Management: Use bosentan 62.5 mg/day or every other day in adult patients taking saquinavir/ritonavir for at least 10 days.  Temporarily stop bosentan (for at least 36 hrs) before starting saquinavir/ritonavir; wait at least 10 days before restarting bosentan.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simvastatin: Bosentan may decrease the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sonidegib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sonidegib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: Bosentan may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Bosentan. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: Bosentan may decrease the serum concentration of Tipranavir. Tipranavir may increase the serum concentration of Bosentan.  Management: Use bosentan 62.5 mg/day or every other day in adult patients taking tipranavir/ritonavir for at least 10 days.  Temporarily stop bosentan (for at least 36 hrs) before starting tipranavir/ritonavir; wait at least 10 days before restarting bosentan.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ulipristal: Bosentan may decrease the serum concentration of Ulipristal. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Velpatasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Velpatasvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Venetoclax. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Bosentan may increase the metabolism of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zolpidem. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142197\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Bioavailability of bosentan is not affected by food. Bosentan serum concentrations may be increased by grapefruit juice. Management: Avoid grapefruit/grapefruit juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142187\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>[US Boxed Warning]: </b>\n      <b>Bosentan is likely to cause major birth defects if used by pregnant women based on animal data. Therefore, pregnancy must be excluded before the start of treatment with bosentan. Throughout treatment and for 1 month after stopping bosentan, women of childbearing potential must use 2 reliable methods of contraception unless the patient has an intrauterine device (IUD) or tubal sterilization in which case no other contraception is needed. Hormonal contraceptives, including oral, injectable, transdermal, and implantable contraceptives, should not be used as the sole means of contraception because these may not be effective in patients receiving bosentan. Obtain monthly pregnancy tests.</b> When a hormonal or barrier contraceptive is used, one additional method of contraception is still needed if a male partner has had a vasectomy. When initiating treatment for women of reproductive potential, a negative pregnancy test should be documented within the first 5 days of a normal menstrual period and &ge;11 days after the last unprotected intercourse. A missed menses or suspected pregnancy should be reported to a healthcare provider and prompt immediate pregnancy testing. Sperm counts may be reduced in men during treatment. Women with pulmonary arterial hypertension (PAH) are encouraged to avoid pregnancy (McLaughlin 2009; Taichman 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2851926\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum  transaminase (AST and ALT) and bilirubin should be determined prior to the initiation of therapy and at monthly intervals thereafter. Monitor for clinical signs and symptoms of liver injury (eg, abdominal pain, fatigue, fever, jaundice, nausea, vomiting). Hemoglobin and hematocrit should be measured at baseline, after 1 and 3 months of treatment, and every 3 months thereafter. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A woman of childbearing potential must have a negative pregnancy test prior to the initiation of therapy, monthly thereafter, and 1 month after stopping therapy.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142169\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Endothelian receptor antagonist that blocks endothelin receptors on endothelium and vascular smooth muscle (stimulation of these receptors is associated with vasoconstriction). Bosentan blocks both ET<sub>A</sub> and ET<sub>B</sub> receptors, with a slightly higher affinity for the A subtype.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142185\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: ~18 L (does not distribute into RBCs)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding, plasma: &gt;98%, primarily to albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP2C9 and 3A4 to three metabolites (one active, contributing ~10% to 20% pharmacologic activity); steady-state plasma concentrations are 50% to 65% of those attained after single dose (most likely due to autoinduction of liver enzymes); steady-state is attained within 3 to 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: ~50%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~5 hours; prolonged with heart failure, possibly in PAH</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: 3 to 5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (as metabolites); urine (&lt;3% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50712434\" class=\"nested sp-pop-child-nested drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;\">Exposure to bosentan reaches a plateau at lower doses in pediatric patients than in adults, and doses &gt;2 mg/kg twice daily do not increase the exposure to bosentan in pediatric patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2854701\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">The addition of bosentan to epoprostenol therapy in 8 children (8-18 years of age) with idiopathic PAH allowed for a reduction in the epoprostenol dose (and its associated side effects) in 7 of the 8 children. Epoprostenol was able to be discontinued in 3 of the 8 children (Ivy, 2004).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2932641\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Tablets are not scored; a commercial pill cutter should be used to prepare a 31.25 mg dose from the 62.5 mg tablet; the half-cut 62.5 mg tablets are stable for up to 4 weeks when stored at room temperature in the high-density polyethylene plastic bottle provided by the manufacturer.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Crushing of the tablets is not recommended; bosentan tablets will disintegrate rapidly (within 5 minutes) in 5 to 25 mL of water to create a suspension. An appropriate aliquot of the suspension can be used to deliver the prescribed dose. Any remaining suspension should be discarded. Bosentan should not be mixed or dissolved in liquids with a low (acidic) pH (eg, fruit juices) due to poor solubility; the drug is most soluble in solutions with a pH &gt;8.5.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23613382\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet,Dispersible</b> (Tracleer Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">32 mg (1): $217.62</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Tracleer Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">62.5 mg (30): $6,528.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg (30): $6,528.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038542\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bosencard (LK);</li>\n      <li>Bosentas (IN, LK);</li>\n      <li>Boxtel (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Lupibose (IN);</li>\n      <li>Pahsentan (KR);</li>\n      <li>Pulmofirst (LK);</li>\n      <li>Pulmoten (BD);</li>\n      <li>Safebo (PH);</li>\n      <li>Stayveer (IE);</li>\n      <li>Tracleer (AT, AU, BB, BE, BR, CH, CN, CO, CR, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, IE, IL, IS, IT, JP, KR, KW, LB, LT, LU, LV, MT, MY, NI, NL, NO, NZ, PA, PH, PL, PT, QA, RO, SA, SE, SG, SI, SK, SV, TH, TW, VN);</li>\n      <li>Usenta (AR, CL, PE);</li>\n      <li>Zuxtana (CR, DO, GT, HN, NI, PA, SV)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Adatia I, &quot;Improving the Outcome of Childhood Pulmonary Arterial Hypertension: The Effect of Bosentan in the Setting of a Dedicated Pulmonary Hypertension Clinic,&quot; <i>J Am Coll Cardiol</i>, 2005, 46(4):705-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/16098439/pubmed\" target=\"_blank\" id=\"16098439\">16098439</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Apostolopoulou SC, Manginas A, Cokkinos DV, et al, &quot;Long-Term Oral Bosentan Treatment in Patients With Pulmonary Arterial Hypertension Related to Congenital Heart Disease: A 2-Year Study,&quot; <i>Heart</i>, 2007, 93(3):350-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/16980516/pubmed\" target=\"_blank\" id=\"16980516\">16980516</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barst RJ, Ivy D, Dingemanse J, et al, &quot;Pharmacokinetics, Safety, and Efficacy of Bosentan in Pediatric Patients With Pulmonary Arterial Hypertension,&quot; <i>Clin Pharmacol Ther</i>, 2003, 73(4):372-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/12709727/pubmed\" target=\"_blank\" id=\"12709727\">12709727</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Beghetti M, &quot;Bosentan in Pediatric Patients With Pulmonary Arterial Hypertension,&quot; <i>Curr Vasc Pharmacol</i>, 2009, 7(2):225-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/19356006/pubmed\" target=\"_blank\" id=\"19356006\">19356006</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Beghetti M, &quot;Current Treatment Options in Children With Pulmonary Arterial Hypertension and Experiences With Oral Bosentan,&quot; <i>Eur J Clin Invest</i>, 2006, 36(Suppl 3):16-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/16919006/pubmed\" target=\"_blank\" id=\"16919006\">16919006</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Beghetti M, Haworth SG, Bonnet D, et al, &quot;Pharmacokinetic and Clinical Profile of a Novel Formulation of Bosentan in Children With Pulmonary Arterial Hypertension: The FUTURE-1 Study,&quot; <i>Br J Clin Pharmacol</i>, 2009a, 68(6):948-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/20002090/pubmed\" target=\"_blank\" id=\"20002090\">20002090</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Beghetti M, Hoeper MM, Kiely DG, et al, &quot;Safety Experience With Bosentan in 146 Children 2-11 Years Old With Pulmonary Arterial Hypertension: Results From the European Postmarketing Surveillance Program,&quot; <i>Pediatr Res</i>, 2008, 64(2):200-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/18414142/pubmed\" target=\"_blank\" id=\"18414142\">18414142</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carter NJ and Keating GM, &quot;Bosentan: In Pediatric Patients With Pulmonary Arterial Hypertension,&quot; <i>Paediatr Drugs</i>, 2010, 12(1):63-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/20034342/pubmed\" target=\"_blank\" id=\"20034342\">20034342</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gilbert N, Luther YC, Miera O, et al, &quot;Initial Experience With Bosentan (Tracleer&reg;) as Treatment for Pulmonary Arterial Hypertension (PAH) Due to Congenital Heart Disease in Infants and Young Children,&quot; <i>Z Kardiol</i>, 2005, 94(9):570-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/16142516 /pubmed\" target=\"_blank\" id=\"16142516 \">16142516 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goissen C, Ghyselen L, Tourneux P, et al, &quot;Persistent Pulmonary Hypertension of the Newborn With Transposition of the Great Arteries: Successful Treatment With Bosentan,&quot; <i>Eur J Pediatr</i>, 2008, 167(4):437-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/17701214/pubmed\" target=\"_blank\" id=\"17701214\">17701214</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ivy DD, Doran A, Claussen L, et al, &quot;Weaning and Discontinuation of Epoprostenol in Children With Idiopathic Pulmonary Arterial Hypertension Receiving Concomitant Bosentan,&quot; <i>Am J Cardiol</i>, 2004, 93(7):943-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/15050507/pubmed\" target=\"_blank\" id=\"15050507\">15050507</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ivy DD, Rosenzweig EB, Lemari&eacute; JC, et al, &quot;Long-Term Outcomes in Chidren With Pulmonary Arterial Hypertension Treated With Bosentan in Real-World Clinical Settings,&quot; <i>Am J Cardiol</i>, 2010, 106(9):1332-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/21029834/pubmed\" target=\"_blank\" id=\"21029834\">21029834</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lunze K, Gilbert N, Mebus S, et al, &quot;First Experience With an Oral Combination Therapy Using Bosentan and Sildenafil for Pulmonary Arterial Hypertension,&quot; <i>Eur J Clin Invest</i>, 2006, 36 Suppl 3:32-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/16919008/pubmed\" target=\"_blank\" id=\"16919008\">16919008</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maiya S, Hislop AA, Flynn Y, et al, &quot;Response to Bosentan in Children With Pulmonary Hypertension,&quot; <i>Heart</i>, 2006, 92(5):664-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/16216850/pubmed\" target=\"_blank\" id=\"16216850\">16216850</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nakwan N, Choksuchat D, Saksawad R, et al, &quot;Successful Treatment of Persistent Pulmonary Hypertension of the Newborn With Bosentan,&quot; <i>Acta Paediatr</i>, 2009, 98(10):1683-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/19523174/pubmed\" target=\"_blank\" id=\"19523174\">19523174</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosenzweig EB, Ivy DD, Widlitz A, et al, &quot;Effects of Long-Term Bosentan in Children With Pulmonary Arterial Hypertension,&quot; <i>J Am Coll Cardiol</i>, 2005, 46(4):697-704.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/16098438/pubmed\" target=\"_blank\" id=\"16098438\">16098438</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sitbon O, Beghetti M, Petit J, et al, &quot;Bosentan for the Treatment of Pulmonary Arterial Hypertension Associated With Congenital Heart Defects,&quot; <i>Eur J Clin Invest</i>, 2006, 36(Suppl 3):25-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bosentan-pediatric-drug-information/abstract-text/16919007/pubmed\" target=\"_blank\" id=\"16919007\">16919007</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Villanueva D. Medical Information Manager, Actelion, personal correspondence, March 2006. </div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13087 Version 174.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708663\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F142201\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F142202\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F2851892\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442087\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F2851924\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F142181\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F142166\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874386\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F2851925\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130909\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F142196\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F2851893\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F6053349\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F142229\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F142186\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F142170\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F142217\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F142174\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F142197\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F142187\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F2851926\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F142169\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F142185\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Pediatric Considerations\" href=\"#F50712434\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F2854701\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F2932641\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F23613382\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038542\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13087|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=bosentan-drug-information\" class=\"drug drug_general\">Bosentan: Drug information</a></li><li><a href=\"topic.htm?path=bosentan-patient-drug-information\" class=\"drug drug_patient\">Bosentan: Patient drug information</a></li></ul></div></div>","javascript":null}